Cardinal Health Inc
$ 225.97
0.51%
24 Feb - close price
- Market Cap 53,174,362,000 USD
- Current Price $ 225.97
- High / Low $ 226.05 / 220.89
- Stock P/E 32.47
- Book Value -12.22
- EPS 6.96
- Next Earning Report 2026-05-07
- Dividend Per Share $2.04
- Dividend Yield 0.91 %
- Next Dividend Date 2026-04-15
- ROA 0.04 %
- ROE N/A %
- 52 Week High 230.81
- 52 Week Low 119.66
About
Cardinal Health, Inc. is an American multinational health care services company.
Analyst Target Price
$248.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-10-30 | 2025-08-12 | 2025-05-01 | 2025-01-30 | 2024-11-01 | 2024-08-14 | 2024-05-02 | 2024-02-01 | 2023-11-03 | 2023-08-15 | 2023-05-04 |
| Reported EPS | 2.63 | 2.55 | 2.08 | 2.1 | 1.93 | 1.88 | 1.84 | 2.08 | 1.82 | 1.73 | 1.55 | 1.74 |
| Estimated EPS | 2.37 | 2.17 | 2.03 | 1.69 | 1.76 | 1.62 | 1.73 | 1.95 | 1.6 | 1.41 | 1.48 | 1.49 |
| Surprise | 0.26 | 0.38 | 0.05 | 0.41 | 0.17 | 0.26 | 0.11 | 0.13 | 0.22 | 0.32 | 0.07 | 0.25 |
| Surprise Percentage | 10.9705% | 17.5115% | 2.4631% | 24.2604% | 9.6591% | 16.0494% | 6.3584% | 6.6667% | 13.75% | 22.695% | 4.7297% | 16.7785% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.77 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-15 | 2026-01-15 | 2025-10-15 | 2025-07-15 | 2025-04-15 | 2025-01-15 | 2024-10-15 | 2024-07-15 | 2024-04-15 | 2024-01-15 |
| Amount | $0.5107 | $0.5107 | $0.5107 | $0.5107 | $0.5056 | $0.5056 | $0.5056 | $0.5056 | $0.5006 | $0.5006 |
Next Dividend Records
| Dividend per share (year): | $2.04 |
| Dividend Yield | 0.91% |
| Next Dividend Date | 2026-04-15 |
| Ex-Dividend Date | 2026-04-01 |
Recent News: CAH
2026-02-25 09:49:51
Coherent Market Insights has released a comprehensive report titled "Infusion Stand Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report provides an in-depth analysis of the market's competition, geographic distribution, growth potential, and key trends, including major players like BD, Baxter International, and Smiths Medical. It aims to offer critical insights for entrepreneurs, investors, and business strategists, covering market performance, risk assessment, and anticipated return on investment across various healthcare settings and regions.
2026-02-24 17:40:00
BD has launched the BD Vacutainer Urine Complete Cup Kit, a three-tube collection system aimed at improving diagnostic accuracy and laboratory efficiency by enabling expanded testing from a single specimen. This new kit is designed to maintain specimen integrity, reduce contamination risks, and streamline workflows, addressing a critical source of diagnostic error in preanalytical processes. The company anticipates this innovation will strengthen its position in the urinalysis market and contribute to revenue growth, with its stock price performance being observed closely.
2026-02-24 13:50:27
Henry Schein, Inc. (HSIC) reported strong fourth-quarter 2025 results, with adjusted EPS of $1.34 and net sales of $3.44 billion, both surpassing Zacks Consensus Estimates. The company experienced significant sales growth across its Dental, Medical, Specialty Products, and Technology segments. Despite revenue beats, both gross and operating margins contracted, attributed to increased cost of sales and SG&A expenses.
2026-02-24 12:52:56
Myriad Genetics, Inc. (MYGN) reported stronger-than-expected Q4 2025 earnings and revenue, leading to a significant jump in its stock price. Despite a 0.4% year-over-year revenue decline, adjusted earnings per share exceeded estimates by 350%. However, the company's gross margin decreased, and Mental Health revenues were negatively impacted by a policy change.
2026-02-24 11:49:51
Cardinal Health's 2026 Biosimilars Report indicates that biosimilars have generated over $56 billion in healthcare savings and are projected to offer up to $181 billion in future savings. The report highlights strong provider confidence, with 99% comfortable explaining biosimilars to patients, and significant advancement in oncology biosimilars achieving 81% market share within five years. Consistent reimbursement is crucial for continued adoption, as nearly 25 new biosimilars are expected to receive FDA approval in various therapeutic areas in the next two years.
2026-02-24 11:49:51
Cardinal Health's 2026 Biosimilars Report indicates that biosimilar drugs have generated over $56 billion in U.S. healthcare savings since 2015 and could save up to $181 billion more if market conditions become favorable. The report also highlights high provider confidence, with 99% of surveyed physicians comfortable explaining biosimilars, and notes that oncology biosimilars achieve an 81% market share within five years. Consistent reimbursement is identified as a critical factor for sustained adoption, with nearly 25 new biosimilars expected to receive FDA approval in the next two years.
